MedicalResearch.com Interview with:
Dr. Michael F. Egan MD
Merck & Co.
North Wales, PA 19454
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: A leading theory of Alzheimer’s Disease is that it is caused by the buildup of amyloid plaques in the brain. Amyloid is composed of a sticky peptide called Abeta. Abeta production can be blocked by Inhibiting an enzyme called BACE. In animal models, BACE inhibtion prevent amyloid accumulation. We aimed to see if a potent BACE inhibitor would slow clinical decline in Alzheimer’s Disease.
EPOCH was a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study evaluating efficacy and safety of two oral doses of verubecestat an investigational BACE inhibitor, administered once-daily versus placebo in patients with mild-to-moderate AD currently using standard of care treatment. The primary efficacy outcomes of the study are the change from baseline in cognition (assessed using the Alzheimer’s Disease Assessment Scale Cognitive Subscale, or ADAS-Cog), as well as the change from baseline in function (assessed using the Alzheimer’s Disease Cooperative Study – Activities of Daily Living, or ADCS-ADL) after 78 weeks of treatment.
Following the recommendation of the external Data Monitoring Committee (eDMC), which assessed overall benefit/risk during the trial, the study was stopped early, as there was “virtually no chance of finding a positive clinical effect.”
Verubecestat did not reduce cognitive or functional decline in patients with mild-to moderate Alzheimer’s disease and was associated with treatment-related adverse events. Continue reading